Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria :~* Patients with type 2 diabetes mellitus diagnosed at least 1 year before the screening visit~* Patient treated for at least 3 months prior to screening visit with one of following OADs at a stable dose of at least usual maintenance dose as described in the label~  * a biguanide (metformin hydrochloride);~ * a thiazolidinedione (TZD) (pioglitazone hydrochloride);~ * an alpha-glucosidase inhibitor (alpha-GI) (acarbose, voglibose or miglitol);~ * or a glinide (nateglinide, repaglinide or mitiglinide);~* Signed written informed consent~Exclusion criteria:~* At screening HbA1c \<7% or \>9.5%;~* At screening: fasting plasma glucose \>250 mg/dL (\>13.9 mmol/L);~* Use of any glucose-lowering agent(s) other than the authorized patient's background treatment defined in I02 (as given in inclusion critieria) within 3 months prior to screening;~* Type 1 diabetes mellitus;~* Women of childbearing potential with no effective contraceptive method;~* Pregnancy or lactation;~* Laboratory findings at the time of screening:~  * Amylase and/or lipase \>3 times the upper limit of the normal laboratory range (ULN);~ * ALT \>3 ULN;~* Any contra-indication to the patient's background oral anti-diabetic treatment;~* History of acute or chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease;~* Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (eg, multiple endocrine neoplasia syndromes);~* Any previous treatment with lixisenatide (eg, participation in a previous study with lixisenatide) or any other GLP1 receptor agonist.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Lixisenatide + Biguanide (Type: EXPERIMENTAL): 52-week treatment with Lixisenatide in combination with biguanide (usual maintenance dose in the label)
- Lixisenatide + TZD (Type: EXPERIMENTAL): 52-week treatment with lixisenatide in combination with TZD (usual maintenance dose in the label)
- Lixisenatide + alpha-GI (Type: EXPERIMENTAL): 52-week treatment with Lixisenatide in combination with alpha-GI (usual maintenance dose in the label)
- Lixisenatide + Glinide (Type: EXPERIMENTAL): 52-week treatment with Lixisenatide in combination with glinide (usual maintenance dose in the label)

Based on this trial design, predict the completion outcome and termination type (if applicable).